PerkinElmer
check quantity

FCGR3A/CD16a (176Val/V158) LANCE Ultra TR-FRET Binding Kit, 10,000 Assay Points

This kit is designed for the quantitative determination of Human FCGR3A/CD16a (176Val/V158) and human Fc fragment binding using a homogeneous (no wash) LANCE Ultra TR-FRET binding assay.

Please enter valid quantity

Please login to add favorites

NULL OR EMPTY CART

Part Number Unit Size List Price Your Price Quantity
TRF1348C 500 Assay Points 750.00 USD
TRF1348M 10,000 Assay Points 10000.00 USD
Buy Now

You successfully added item(s) to your cart

Overview

The LANCE® Ultra FCGR3A/CD16a (176Val/V158) Binding Kit is designed for quantitative determination of Fc-receptor binding using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

  • No-wash steps, no separation steps
  • TR-FRET technology
  • Sensitive detection
  • High reproducibility
  • Faster time-to-results
  • Easy automation
  • 96-well, 384-well, and 1536-well formats

LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One protein of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second protein is labeled with an acceptor fluorophore [ULight™ dye]. Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.

The Fc-Gamma Receptors (FCGRs) are members of immunoglobulin superfamily and play a critical role in the function of therapeutic antibodies. FCGRs are divided into three classes and FCGR3 (CD16) is expressed as two distinct forms (FCGR3A and FCGR3B) encoded by two different highly homologous genes in a cell type specific manner. FCGR3A is a low/intermediate affinity receptor for polyvalent immune-complexed IgG. It is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody-dependent cellular cytotoxicity (ADCC), mast cell degranulation and clearance of immune complexes. In humans, a single nucleotide polymorphism creates two isoforms: high binding (176Val/V158) and low binding (176Phe/F158) forms that, when homozygous, may influence susceptibility to autoimmune diseases or response to therapeutic IgG antibodies. FCGR3A has been considered as an important therapeutic target. This LANCE Ultra assay can be used to determine the binding activity of human IgG Fc fragment to human FCGR3A and also can be used to study how other antibodies bind to FCGR3A by competition assay.

Disclaimer:  For research use only. Not for use in diagnostic procedures.

Specifications

Assay Target FCGR3A
Assay Target Class Fc-receptor
Automation Compatible Yes
Detection Method Time-Resolved Fluorescence (TRF), TR-FRET
Experimental Type In vitro
Product Brand Name LANCE Ultra
Shipping Condition Blue Ice
Target Species Human
Therapeutic Area Biologics/Bioprocess
Unit Size 10,000 Assay Points

Resources, Events & More

Resource Type File Name File Format
Brochure LANCE product listing PDF  77 KB
Application Note Fc-Receptor Binding ADCC Assays Utilizing LANCE Ultra Technology: Characterization of hIgGs and FcγR PDF  1 MB
Manual LANCE Ultra Fc-receptor (176Val/V158) binding assay PDF  720 KB